What is Gastrointestinal Stromal Tumors ?

A gastrointestinal stromal tumor, commonly referred to as a GIST, is a specific and rare type of soft-tissue sarcoma. The tumors develop from connective tissues throughout the digestive tract rather than the normal epithelial cancer pathway, which begins with carcinoma development. The body produces GIST tumors by transforming interstitial cells of Cajal (ICCs) into stem cells. The specialized cells in the body act as the gut's electrical pacemakers, sending signals that maintain the rhythmic muscle contractions (peristalsis) that propel food through the digestive system.

A GIST tumor can develop anywhere from the esophagus to the rectum in the gastrointestinal tract. However, doctors find these tumors most frequently in the stomach (60%) and small intestine (30%) of patients. The tumors develop within organ walls, allowing them to grow to large sizes before patients notice any symptoms.

What are the Symptoms & Causes of Gastrointestinal Stromal Tumors ?

Recognizing the Signs of GIST

The majority of cases show GIST as a silent tumor that remains undetected until doctors conduct imaging tests for other abdominal conditions. Clinical signs begin to emerge when the tumor expands or exerts pressure on adjacent structures. The most common symptom is painless gastrointestinal bleeding. A patient who experiences brisk bleeding may vomit blood or pass bright red stools. Chronic, slow bleeding results in anemia, which causes patients to feel tired and dizzy and to develop pale skin.

Patients show the following physical signs:

• Abdominal Distension: An observable swelling or hardened mass that doctors can detect through physical examinations.
• Early Satiety: A feeling of being "full" after eating only a few bites of food, which happens when the tumor pushes against the stomach area.
• Abdominal Cramping: The patient experiences continuous abdominal pain that resembles the symptoms of indigestion or bowel obstruction.
• Nausea: The person often loses their appetite and experiences unintended weight loss.

Understanding the Genetic Triggers

The vast majority of GIST cases show no connection between their development and personal lifestyle habits or environmental exposure to toxic substances. The development of cancer results from specific genetic "glitches" within the genome. The majority of GisTs (80%) harbor a KIT mutation, leading to permanent KIT protein activation throughout the body. The protein activates a constant cellular signal, which prompts cells to continue dividing when they should typically undergo natural death.

The second most common genetic alteration occurs in 10% of patients with a PDGFRA gene mutation. The majority of GisTs arise without known causes. However, some cases result from hereditary diseases such as Neurofibromatosis type 1 (NF1) and Carney-Stratakis syndrome. Identifying these mutations is the primary method for treating GIST patients because it enables doctors to determine which drugs will provide the greatest efficacy against the condition.

How Gastrointestinal Stromal Tumors Diagnosed & Tested ?

The diagnosis of GIST requires both high-resolution imaging and pathological test results for confirmation. The visual endoscopy method allows doctors to see only a bulge in intramural tumors, as these tumors grow within the wall of the body.

• Computed Tomography (CT) with Contrast: This system provides doctors with their most crucial imaging tool for visualizing tumors, showing tumor dimensions, blood circulation patterns, and how they interact with nearby structures. The system enables doctors to evaluate GIST metastasis, which commonly occurs in the liver.
• Endoscopic Ultrasound (EUS): It is an examination technique in which a physician uses an endoscope with an ultrasound probe to visualize the different layers of the stomach and intestines and determine the true growth layer of the tumor.
• Fine-Needle Aspiration (FNA) Biopsy: A tissue sample may be obtained during an EUS using a thin needle. GisTs show strong similarities to other tumors, including leiomyomas. This makes differential diagnosis difficult because doctors rely on standard scans to identify tumors.
• Immunohistochemistry: Pathologists search for the CD117 protein in tissue samples. The presence of this protein is the "gold standard" for confirming a GIST diagnosis.
• Mutational Analysis: The laboratory test is a specialized examination to detect specific KIT or PDGFRA mutations. The oncology team uses the mutation type to anticipate which particular targeted drug therapies will effectively treat the tumor.

What are the Management and Treatment Options for GIST?

The process of managing GIST cases requires personalized treatment plans that depend on three factors: tumor location, tumor size, and tumor mitotic rate (the rate at which cells divide).

Surgical Options

Surgical resection stands as the primary treatment method for localized tumors that have not yet spread throughout the body. The surgeon needs to achieve tumor removal through surgical methods that maintain "clear margins," which require no cancer cells to remain at the edges of the extracted tissue. GisTs have a low tendency to spread to lymph nodes, so most cases do not require extensive node dissection. Patients who have tumors of different sizes can receive laparoscopic (minimally invasive) surgery as their treatment option because this surgery enables them to recover faster and experience reduced postoperative pain.

Targeted Therapy (Precision Medicine)

The introduction of Tyrosine Kinase Inhibitors (TKis) brought major advances to GIST treatment. GIST demonstrates resistance to traditional chemotherapy and radiation treatments. Oral medications like Imatinib (Gleevec) are used to treat cancer because they prevent signals that promote tumor growth.

• Neoadjuvant Therapy: Imatinib treatment starts before surgery when doctors want to shrink a large tumor so they can safely remove it.
• Adjuvant Therapy: After surgery, high-risk patients can take Imatinib for three years to stop their tumors from returning.

What is Outlook / Prognosis of Gastrointestinal Stromal Tumors?

GIST patients now have better long-term outcomes than they did two decades ago. The prognosis depends on a recurrence risk assessment that uses tumor size and mitotic count to determine the outcome.

• Localized GIST: When doctors completely remove small tumors, patients achieve a 5-year survival rate typically exceeding 90%.
• Metastatic GIST: Most patients with cancer that has spread to their liver and abdomen can enjoy life for several years because targeted therapies work effectively.
• Long-Term Monitoring: Doctors require GIST patients to undergo CT scans every 5 to 10 years because the disease can recur after completing their first treatment.

Why choose Tender Palm Super-Speciality Hospital for Gastrointestinal Stromal Tumors (GIST) Treatment in Lucknow, India?

Tender Palm Super-Speciality Hospital offers advanced Gastrointestinal Stromal Tumors treatment in Lucknow, India, at an affordable cost. We have a team of experienced gastrointestinal surgeons and oncology specialists who provide accurate diagnosis and both non-surgical and surgical treatment options including surgical resection, targeted tyrosine kinase inhibitor therapy, and comprehensive oncological management procedures. Our Gastrointestinal Surgery and Oncology team has decades of experience in successfully treating Gastrointestinal Stromal Tumors in Lucknow, India.

To seek an Expert consultation for Gastrointestinal Stromal Tumors (GIST) Treatment in Lucknow, India:

Call us at +91-9076972161
Email at care@tenderpalm.com

Request a Call Back